Repligen (RGEN) versus Cellular Biomedicine Group (CBMG) Financial Review

Repligen (NASDAQ:RGEN) and Cellular Biomedicine Group (NASDAQ:CBMG) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional & Insider Ownership

92.5% of Repligen shares are owned by institutional investors. Comparatively, 8.3% of Cellular Biomedicine Group shares are owned by institutional investors. 1.4% of Repligen shares are owned by company insiders. Comparatively, 8.3% of Cellular Biomedicine Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Repligen and Cellular Biomedicine Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen 0 3 4 0 2.57
Cellular Biomedicine Group 0 1 1 0 2.50

Repligen currently has a consensus target price of $50.17, suggesting a potential downside of 7.92%. Cellular Biomedicine Group has a consensus target price of $38.00, suggesting a potential upside of 109.25%. Given Cellular Biomedicine Group’s higher probable upside, analysts clearly believe Cellular Biomedicine Group is more favorable than Repligen.


This table compares Repligen and Cellular Biomedicine Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repligen 13.49% 5.05% 4.02%
Cellular Biomedicine Group -10,133.88% -47.52% -44.44%

Volatility & Risk

Repligen has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Cellular Biomedicine Group has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500.

Valuation and Earnings

This table compares Repligen and Cellular Biomedicine Group’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Repligen $141.24 million 16.90 $28.35 million $0.69 78.96
Cellular Biomedicine Group $340,000.00 905.86 -$25.49 million ($1.78) -10.20

Repligen has higher revenue and earnings than Cellular Biomedicine Group. Cellular Biomedicine Group is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.


Repligen beats Cellular Biomedicine Group on 10 of the 14 factors compared between the two stocks.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.

Leave a Reply